TT
Tresquare Technologies develops a transcatheter device to resect and remove leaflets from failing aortic bioprostheses during Valve-In-Valve (ViV) procedures. Their device aims to prevent coronary obstruction and patient-prosthesis mismatch, while also reducing complications like paravalvular leakage and thrombus formation, ultimately improving the durability of TAVR implants.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Tresquare Technologies develops a transcatheter device to resect and remove leaflets from failing aortic bioprostheses during Valve-In-Valve (ViV) procedures. Their device aims to prevent coronary obstruction and patient-prosthesis mismatch, while also reducing complications like paravalvular leakage and thrombus formation, ultimately improving the durability of TAVR implants.